We therefore aimed to assess whether MCI-LB featured a plasma biomarker profile of lowered Aβ42/40 ratio, increased phosphorylated tau, GFAP and NfL in comparison to healthy older adults, whether this differed from MCI-AD, and which markers best discriminated MCI and its subtypes from normal ageing. The gene discussed is GFAP; the disease is Alzheimer disease.